PT  - JOURNAL ARTICLE
AU  - Richardson, Simone I.
AU  - Madzorera, Vimbai Sharon
AU  - Spencer, Holly
AU  - Manamela, Nelia P.
AU  - van der Mescht, Mieke A.
AU  - Lambson, Bronwen E.
AU  - Oosthuysen, Brent
AU  - Ayres, Frances
AU  - Makhado, Zanele
AU  - Moyo-Gwete, Thandeka
AU  - Mzindle, Nonkululeko
AU  - Motlou, Thopisang
AU  - Strydom, Amy
AU  - Mendes, Adriano
AU  - Tegally, Houriiyah
AU  - de Beer, Zelda
AU  - de Villiers, Talita Roma
AU  - Bodenstein, Annie
AU  - van den Berg, Gretha
AU  - Venter, Marietjie
AU  - de Oliviera, Tulio
AU  - Ueckermann, Veronica
AU  - Rossouw, Theresa M.
AU  - Boswell, Michael T.
AU  - Moore, Penny L.
TI  - SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated individuals
AID  - 10.1101/2022.02.10.22270789
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.02.10.22270789
4099  - http://medrxiv.org/content/early/2022/03/22/2022.02.10.22270789.short
4100  - http://medrxiv.org/content/early/2022/03/22/2022.02.10.22270789.full
AB  - The SARS-CoV-2 Omicron variant escapes neutralizing antibodies elicited by vaccines or infection. However, whether Omicron triggers cross-reactive humoral responses to other variants of concern (VOCs) remains unknown. We use plasma from 20 unvaccinated and seven vaccinated individuals infected by Omicron BA.1 to test binding, Fc effector function and neutralization against VOCs. In unvaccinated individuals, Fc effector function and binding antibodies target Omicron and other VOCs at comparable levels. However, Omicron BA.1-triggered neutralization is not extensively cross-reactive for VOCs (14 to 31-fold titer reduction) and we observe 4-fold decreased titers against Omicron BA.2. In contrast, vaccination followed by breakthrough Omicron infection was associated with improved cross-neutralization of VOCs, with titers exceeding 1:2,100. This has important implications for vulnerability of unvaccinated Omicron-infected individuals to reinfection by circulating and emerging VOCs. While Omicron-based immunogens may be adequate boosters, they are unlikely to be superior to existing vaccines for priming in SARS-CoV-2 naïve individuals.Competing Interest StatementThe authors have declared no competing interest.Funding StatementPLM is supported by the South African Research Chairs Initiative of the Department of Science and Innovation and National Research Foundation of South Africa, the SA Medical Research Council SHIP program, the Centre for the AIDS Programme of Research in South Africa (CAPRISA). We acknowledge funding from the Bill and Melinda Gates Foundation, through the Global Immunology and Immune Sequencing for Epidemic Response (GIISER) program. SIR is a LOreal/UNESCO Women in Science South Africa Young Talents awardee.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was received from the University of Pretoria, Human Research Ethics Committee (Medical) (247/2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors